Hi, it's Lacey Healy.

When members of Congress and even the vice president are sworn into office, they say an oath,

to protect the country from all enemies, foreign and domestic.

But what does a domestic enemy look like?

January 6, it was coming from the top.

Some of them are bad people, but most of them are just normal people.

Because if we weren't all stressed out enough.

This season on Things That Go Boom, we're turning our eyes on the U.S., how violence starts, how it stops, and how we stop it before it starts.

A new season of Things That Go Boom is available now wherever you get your podcasts.

Imagine you're in charge of a huge pharmaceutical company.

If your scientists developed the busiest new medication in decades,

something in unprecedented demand that patients might need for the rest of their lives,

that would be a very big thing.

And the potential profits might surely justify any ramping up of production facilities around the world to meet demand.

Given that thought exercise, it might surprise you to learn that at the Danish company

Novo Nordisk, the astonishing success of OZempic is generating mixed emotions.

From KERA in Dallas, this is think. I'm Chris Boyd.

OZempic was originally developed to help people with type 2 diabetes,

and it can. But its most celebrated side effect, significant diminishment of appetite that often

leads to weight loss, has convinced many millions of people that they want this drug or a

competitor in the same class. And that has created some conflicts for Novo Nordisk, which has long operated first and foremost

in service to people with diabetes, including those who cannot live without supplemental

...